Psoriatic arthritis drug apremilast tracked for two years in Real-World study
NCT ID NCT03106051
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study followed 526 adults with active psoriatic arthritis who were already prescribed apremilast (Otezla) by their doctors. Researchers observed them for up to 100 weeks to see how well the drug controlled their symptoms in everyday practice. The goal was to gather long-term data on effectiveness and safety outside of a controlled trial.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
apremilast (Otezla)
What this could lead to
If successful, this study could confirm that apremilast is a safe and effective long-term option for managing psoriatic arthritis symptoms in everyday practice.
What could go wrong
This is an observational study, not a controlled trial, so results may be less reliable. It does not test a new treatment, only documents existing use, and long-term benefits or risks remain uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ARTHRITIS, PSORIATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Klinikum Stephansplatz
Hamburg, 20354, Germany
-
Rheumatology at Struenseehaus
Altona, Free and Hanseatic City of Hamburg, 22767, Germany